Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose chemotherapy

Leukemia and Lymphoma

Volumn 43, Issue 12, 2002, Pages 2351-2353

  Andersson, P O ^a   Braide, I ^a   Hilsson Ehle, H ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ALCL; Lymphoma; Relapse; Trofosfamide

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CORTICOSTEROID; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOGUAZONE; TROFOSFAMIDE; VINBLASTINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE;

ADULT; ALLOGRAFT; ANAPLASTIC CARCINOMA; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; EPISTAXIS; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; MUCOSA INFLAMMATION; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL TIME; DISEASE FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; RECURRENT DISEASE; REMISSION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, LARGE-CELL, KI-1; MALE; PALLIATIVE CARE; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 0036891149     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000040053     Document Type: Article

References (16)

1. Stein, H., Foss, H.D., Durkop, H., Marafioti, T., Delsol, G., Pulford, K., Pileri, S. and Falini, B. (2000) "CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features", Blood 96, 3681-3695.
2. Falini, B., Pileri, S., Zinzani, P.L., Carbone, A., Zagonel, V., Wolf-Peeters, C., Verhoef, G., Menestrina, F., Todeschini, G., Paulli, M., Lazzarino, M., Giardini, R., Aiello, A., Foss, H.D., Araujo, I., Fizzotti, M., Pelicci, P.G., Flenghi, L., Martelli, M.F. and Santucci, A. (1999) "ALK + lymphoma: clinico-pathological findings and outcome", Blood 93, 2697-2706.
3. Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., Morris, S.W., Connors, J.M., Vose, J.M., Viswanatha, D.S., Coldman, A. and Weisenburger, D.D. (1999) "Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma", Blood 93, 3913-3921.
4. Fanin, R., Ruiz de Elvira, M.C., Sperotto, A., Baccarani, M. and Goldstone, A. (1999) "Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)", Bone Marrow Transplantation 23, 437-442.
5. Helsing, M.D. (1997) "Trofosfamide as a salvage treatment with low toxicity in malignant lymphoma. A phase II study", European Journal of Cancer 33, 500-502.
6. Salminen, E., Nikkanen, V. and Lindholm, L. (1997) "Palliative chemotherapy in non-Hodgkin's lymphoma", Oncology 54, 108-111.
7. Wist, E. and Risberg, T. (1991) "Trofosfamide in non-Hodgkin's lymphoma. A phase II study", Acta Oncologica 30, 819-821.
8. Potzi, P., Aiginger, P. and Kuhbock, J. (1979) "Ixoten therapy in malignant lymphomas", Acta Medica Austriaca 6, 247-249.
9. Dhedin, N., Giraudier, S., Gaulard, P., Esperou, H., Ifrah, N., Michallet, M., Milpied, N., Rio, B., Cahn, J.Y., Molina, L., Laporte, J.L., Guilhot, F. and Kuentz, M. (1999) "Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle", British Journal of Haematology 107, 154-161.
10. Juckett, M., Rowlings, P., Hessner, M., Keever-Taylor, C., Burns, W., Camitta, B., Casper, J., Drobyski, W.R., Hanson, G., Horowitz, M., Lawton, C., Margolis, J., Peitryga, D. and Vesole, D. (1998) "T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up", Bone Marrow Transplantation 21, 893-899.
11. Mendoza, E., Territo, M., Schiller, G., Lill, M., Kunkel, L. and Wolin, M. (1995) "Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma", Bone Marrow Transplantation 15, 299-303.
12. Stein, R.S., Greer, J.P., Goodman, S., Brandt, S.J., Morgan, D., Macon, W.R., McCurley, T.L. and Wolff, S.N. (2001) "Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma", Leukemia and Lymphoma 41, 343-352.
13. Boos, J., Kupker, F., Blaschke, G. and Jurgens, H. (1993) "Trofosfamide metabolism in different species-ifosfamide is the predominant metabolite", Cancer Chemotherapy and Pharmacology 33, 71-76.
14. Matar, P., Rozados, V.R., Gonzalez, A.D., Dlugovitzky, D.G., Bonfil, R.D. and Scharovsky, O.G. (2000) "Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide", European Journal of Cancer 36, 1060-1066.
15. Awwad, M. and North, R.J. (1988) "Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden", Immunology 65, 87-92.
16. Tzai, T.S., Lin, J.S. and Chow, N.H. (1996) "Modulation of antitumor immunity of tumour-bearing mice with low-dose cyclophosphamide", Journal of Surgery Research 65, 139-144.